PTP-01

Phase 3Small molecule

DDoron Therapeutics Inc.

PTP-01 is one of 15 small molecule programs targeting Knee Osteoarthritis. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Knee OsteoarthritisRecruiting

Knee OsteoarthritisPhase 3

Recruiting

Competition

Competitive Landscape

15 competitors in Knee Osteoarthritis

#DrugCompanyPhaseTrials

Cymbalta

Jazz Pharmaceuticals

Approved

2 2

Inulin and Sodium Chloride

BBlue Earth Diagnostics

Phase 2

1 3

Surgicel

PPeking University Third Hospital

Phase 3

—4

PTP-01

DDoron Therapeutics Inc.

Phase 3

1 5

Medrol

Pfizer

Preclinical

1 6

Allocetra

EEnlivex Therapeutics Ltd.

Phase 2

1 7

Decadron

AAspen Global Incorporated

Preclinical

2 8

Precedex

MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.

Preclinical

2 9

Solu-Medrol

MMassachusetts Eye and Ear Infirmary

Preclinical

1 10

Paracetamol

GSK

Preclinical

—

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2027

Phase 3Recruiting

Knee Osteoarthritis

NCT07219771

Clinical

Trials by Indication[1]

Pancreatic Cancer1 trial

Phase 0 Biodistribution of Novel Imaging for Resectable Pancreatic Cancer

Terminated·UUniversity of Virginia·Phase 1·NCT01962909·3 enrolled

Knee Osteoarthritis1 trial

A Multicenter, Prospective, Randomized, Double-Blind, Placebo-Controlled, Parallel-Arm, Phase 3 Study of Intra-Articular Administration of an Allogeneic Human Placental Tissue Particulate (PTP-001) for the Treatment of Knee Osteoarthritis

Recruiting·DDoron Therapeutics Inc.·Phase 3·NCT07219771·300 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for PTP-01. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — PTP-01 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for PTP-01. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Doron Therapeutics Inc. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: DDoron Therapeutics Inc.

PTP-01

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2027

Trials by Indication[1]

Pancreatic Cancer1 trial

Knee Osteoarthritis1 trial

References

Drug Info

Quick Facts

Related News